In the last 12 months, landmark trials including “Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA)” and the “Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF)” have potentially changed the landscape of atrial fibrillation (AF) ablation. 

This webinar will explore the role of catheter ablation of atrial fibrillation in patients with heart failure and demonstrate the multitude of beneficial clinical endpoints including mortality (CASTLE-AF), improved QOL, reduced hospital admissions, and cost effectiveness.